Product Information
DILTIAZEM 24H ER(CD) 300 MG CP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.3005 per EA under NDC 68382059805. Its NADAC has been published 397 times since Jan 30, 2019.
FDA first approved this application on Aug 8, 2017. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382059805
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206534FDA Approved
8/8/2017
TE Code
AB3
On Market Since
9/28/2017
Pharmacological Classes
Price Statistics
The NADAC for DILTIAZEM 24H ER(CD) 300 MG CP has been published 397 times since Jan 30, 2019, and over the history we have for it it has declined 38.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3005 per EA |
|---|---|
| All-time high | $0.5656 (Aug 14, 2019) |
| All-time low | $0.2613 (Apr 19, 2023) |
| 52-week high | $0.3098 |
| 52-week low | $0.2943 |
| Median price | $0.3312 |
| Average price | $0.3790 |
| Largest weekly change | +35.3% (Aug 21, 2024) |
| Weeks tracked | 397 |
| Tracking since | Jan 30, 2019 |
1W
N/A
1M
N/A
3M
+0.7%
6M
-3.0%
1Y
+0.4%
3Y
-6.0%
5Y
-19.6%
All
-38.4%
Last surveyed Sep 2, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diltiazem hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DILTIAZEM 24H ER(CD) 300 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DILTIAZEM 24H ER(CD) 300 MG CP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.3005 per EA (NDC 68382059805), effective Sep 2, 2026.
How has the price of DILTIAZEM 24H ER(CD) 300 MG CP changed over time?
Over the history we have for it, the NADAC for DILTIAZEM 24H ER(CD) 300 MG CP has declined 38.4%. It has been tracked across 397 weekly CMS publications since Jan 30, 2019.
What are the highest and lowest recorded NADAC prices for DILTIAZEM 24H ER(CD) 300 MG CP?
Since Jan 30, 2019, the NADAC for DILTIAZEM 24H ER(CD) 300 MG CP has ranged from a low of $0.2613 (Apr 19, 2023) to a high of $0.5656 (Aug 14, 2019), with a median of $0.3312 per EA.
Are there cheaper alternatives to DILTIAZEM 24H ER(CD) 300 MG CP?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TIADYLT ER 300 MG CAPSULE, is $0.2616 per EA — about 13% below DILTIAZEM 24H ER(CD) 300 MG CP.
Who manufactures DILTIAZEM 24H ER(CD) 300 MG CP?
DILTIAZEM 24H ER(CD) 300 MG CP (NDC 68382059805) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.